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Objectives. This study sought to determine whether the location 
of coronary spastic activity may change over time in patients with 
persistent variant angina. 
Background. Although electrocardiographic studies have pro- 
vided indirect evidence to indicate that the location of ischemia 
may change in patients with variant angina, it has not been tested 
by quantitative angiography whether the location of vasospastic 
activity may change over time. 
Methods. Paired ergonovine provocation tests and coronary 
angiography were performed at a mean (-+SD) interval of 43 +- 13 
months apart in patients with persistent symptoms ofvasospastic 
angina in the absence of significant atherosclerosis. A total of 87 
spastic and nonspastic segments of87 major vessels in 29 patients 
were analyzed by quantitative angiography atbaseline, after the 
administration of ergonovine and after isosorbide dinitrate at the 
initial and follow-up tests. 
Results. In 13 patients (group 1), coronary spasm was observed 
in the same 16 coronary segments at both the initial and follow-up 
ergonovine provocation tests. In 16 patients (group 2), the follow- 
ing angiographic changes occurred between the initial and 
follow-up tests in 48 major vessels: Of the 23 segments that 
developed spasm at the initial test, 10 did not have spasm at the 
follow-up test; of the 25 vessels that did not demonstrate spasm on 
the initial test, 12 demonstrated spasm on the follow-up test (a 
new site of spasm). Thus, in 22 (46%) of 48 vessels, fluctuation of 
spastic location was observed at follow.up. 
Conclusions. Quantitative coronary angiography and repeated 
ergonovine tests revealed that some patients with persistent 
vasospastic angina demonstrate fluctuation of vasospastic loca- 
tion, whereas others exhibit a fixed location of vasospasm. Vaso- 
spastic angina may not only be a transient disease restricted in 
location, but may also be a persistent and variable condition 
involving multiple vessels over many ears. 
(J Am Coil Cardio11995;26:1606-14) 
Coronary spasm plays a role in a wide spectrum of ischemic 
coronary events, including variant angina and some cases of 
unstable angina and acute myocardial infarction (1-13). Al- 
though vasospastic anginal symptoms have undergone sponta- 
neous remission in some patients with variant angina (14-17), 
persistent symptoms have been observed over many years in 
other patients without significant atherosclerosis (17-20). Al- 
though Kaski et al. (21) observed that coronary spasm may 
remain active over years in the same coronary segments 
despite medical therapy, other investigators (14,22,23) demon- 
strated variability of electrocardiographic (ECG) changes dur- 
ing repeated ergonovine tests and recurrent spontaneous at- 
tacks. However, whether the location and degree of vasospasm 
may change over a period of several years has not yet been 
established quantitatively. 
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Although many clinical studies (4,6,8,9,15,21) have shown 
that coronary spasm frequently occurs at sites of advanced 
atherosclerosis, Conti et al. (7) suggested that the presence of 
significant atherosclerosis may reduce the role of vasospasm in
ischemic attacks. To determine the long-term role of vasospas- 
tic activity and its variation in location, we repeated ergonovine 
provocation tests in patients without advanced atherosclerosis 
but with persistent symptoms of variant angina t an average 
interval of 43 months apart, using a computer-based quantita- 
tive coronary angiographic analysis ystem (CAAS II). 
Methods  
Criteria of vasospastic angina. The following criteria of 
vasospastic angina were used: 1) chest pain at rest associated 
with ST segment changes >0.2 mV on the ECG; 2) pain relief 
immediately after administration f nitroglycerin; 3) no subse- 
quent evidence of myocardial infarction; 4) ergonovine- 
provoked coronary spasm associated with chest pain and 
ischemic ECG changes. Coronary spasm was defined as 1) a 
transient total or nearly total occlusion reversible with isosor- 
bide dinitrate, or 2) a transient, significant (>50%) narrowing 
reversible with isosorbide dinitrate in normal or nearly normal 
segments (24-26). We used the ergonovine provocation test 
because ithas been found (27-29) to have a high sensitivity and 
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Table 1. Clinical and Angiographic Characteristics of 29 Patients With Vasospastic Angina 
ST Segment Changes During Spasm Percent Fixed Stenosis at Spastic Site After ISDN 
Age (yr)/ 
Pt No. Gender Initial ECG Follow-Up ECG Initial Angiogram Follow-Up Angiogram 
Group 1 
1 56/M 111, aVF lit, aVF 21% seg 1 15% seg 1 
2 63/M V2-V 4 V2-V 4 45~" seg 7 41% seg 7 
3 63/M 11, IIl, aVF II, lII, aVF 35% seg 11 38% seg 11 
4 67/M II. IlL aVF [I, III, aVF 229~ seg 2, 27% seg 13 16% seg 2, 31% seg 13 
5 49/M Ill. aVF. V:~-V~ lIl, aVF, V3-V 5 19% seg 2, 34% seg 6 31% seg 2, 27% seg 6 
6 57/M II, Ill, aVF II, lII, aVF 28% seg 2 24% seg 2 
7 61/M 11, IIl, aVF, V~. II, Ill, aVF, V,, 42% seg 1, 29% seg 13 28% seg 1, 15% seg 13 
8 54/M It, Ill, aVF 11, Ill, aVF 22% seg 2 27% seg 2 
9 55/M 1I, Ill, aVF II, IIl, aVF 18% seg 1 15% seg 1 
10 41/M V~-V~ V2-V 4 24% seg 7 28% seg 7 
11 57/M 11, Ill, aVF. V,, I1, III, aVF, V, 31% seg 13 22% seg 13 
12 48/F II1, aVF, V~. Ill, aVF, V 6 49% seg 13 39% seg 13 
13 54/M I[, lII, aVF II, III, aVF 3°;~ seg 1 25% seg 1 
Group 2 
14 62/M V2-~ a 11, II1. aVF 42~i seg 7, 18% scg 13 13% seg 13 
15 57/F II, Ill, aVF [1, IIl, V2-V 5 17~ seg 3 13% seg 2, 29% seg 7, 25% seg 13 
16 54/M 11, Ill, aVF, V;-V 4 lI, llI, aVF 29% seg 1, 19% seg 7, 23% seg 11 39% seg 1 
17 42/M V2-V ~ II, lIl, aVF 25% seg 7 16% seg 3 
18 52/M Ill, aVF. V: V~ II, lII, aVF 7% seg 4, 14g seg 7 20% seg 4, 21% seg 11 
19 56/M V~-V~ II, lIl, V3-V 4 17% scg 7 14% seg 1, 47% seg 7 
20 68/'M Ill, aVF Ill, aVF, V,-V4 30% seg 11 20% seg 6, 36% seg 11 
21 58/F 11, lII. aVF [1, Ill, aVF, V2-V, 20c~ seg 4 25% seg 4, 25% seg 7 
22 62/M II, 1I[. aVF II, 111, aVF, V~, 9% seg 2, 29% seg 13 42% seg 13 
23 66/M 11I. aVF, V4-V, 1I, III, aVF 13c::~ seg 3, 17%, seg 13 36% seg 13 
24 44/M Vz-V ~ II, III, aVF 2% seg 2, 29% seg 6 19% seg 2 
25 50/M \/I-V~ II. 111, aVF 7% seg 6 24% seg 2 
26 61/M II, Ill, aVF [1, lI1, aVF, V2-V 4 16% seg 2 19% seg 1, 29% seg 7 
27 37/M II, llI, aVF I1, IlL aVF, V~, 17% seg l 31% seg 1, 6% seg 13 
28 46/M V2-Vs, l, aVl 11, llI. aVF ',18% seg 6 45% scg 2 
29 43/M AVI, V5-V,, 11, lIi, aVF, V~ 18% seg 11 6% seg 3, 26% seg 11 
ECG = electrocardiogram; F = female: ISDN isosorbide dinitrate; M - male: Pt = patient; seg = coronary segment as defined by the American Heart 
Association classification (43). 
specificity for, and short-term reproducibility of, spontaneous 
anginal attacks in patients with vasospastic angina. Follow-up 
angiography and provocation testing were performed to esti- 
mate the progression ofatherosclerosis as well as to determine 
the location of vasospastic activity and to provide information 
on the necessity to continue long-term medication. 
Study patients. Because the purpose of the present study 
was to examine the role of pure vasospasm in ischemic attacks 
during long-term follow-up, we excluded patients with signifi- 
cant atherosclerosis (>50% diameter stenosis after adminis- 
tration of isosorbide dinitrate). The study group was selected 
from a total of 50 patients with variant angina who had 
undergone long-term angiographic and ergonovine provoca- 
tion follow-up. Of the 50 patients who had chest pain at rest 
with ischemic ST segment changes at the time of the initial 
angiographic study, vasospastic anginal symptoms were persis- 
tent during the follow-up period in 34. In the remaining 16 
patients, symptoms of vasospastic angina resolved during 
follow-up, and these 16 patients were excluded from the study. 
Of the former 34 patients, 5 who developed significant, fixed 
stenosis (>50% diameter stenosis after administration of 
isosorbide dinitrate) during follow-up were excluded from the 
study. Of the remaining 29 patients, 13 had persistent symp- 
toms of vasospastic angina with ischemic ST segment changes 
during the follow-up period, and vasospasm was reproduced at
the same coronary segment at the follow-up angiogram (group 
1 ); 16 patients had persistent symptoms of vasospastic angina 
with ischemic ST segment changes during the follow-up period, 
and vasospasm occurred in different vessels at follow-up 
(group 2). 
Isehemic episode during follow-up, Vasospastic anginal 
activity was assessed by anginal symptoms, 12-lead ECG 
monitoring during anginal attacks and ambulatory in-hospital 
ECG monitoring or Holter monitoring out of hospital in all 
patients. All 29 patients had intermittent chest pain with ST 
segment changes at the time of the initial angiographic study 
(Table 1). These attacks were frequently observed over a 
period of a few days to several weeks (so-caUed hot phases of 
the disease [21]). The medication, combined with a calcium 
antagonist (diltiazem) and sustained-release i osorbide dini- 
trate (Table 2), was effective and reduced the frequency of 
ischemic attacks in both groups; however, vasospastic angina 
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Table 2. Clinical Characteristics of Groups 1 and 2 
Group 1 Group 2 p 
(n - 13) (n = 16) Value 
Age (yr) 5(7 : 7 54 _+ 9 0.50 
M/F 12/1 14/2 0.85 
Coronary risk factors 
Hypertension 2 3 0.80 
Diabetes 1 1 0.56 
Smoking 12 14 0.85 
Hypercholesterolemia 1 1 0.55 
Serum cholesterol (mg/day) 
Initial test 191 - 33 188 _+ 28 0.82 
Follow-up test 197 + 39 194 _+ 29 0.81 
Interval of tests (mo) 
20 -29 2 2 0.85 
30-39 3 5 11.94 
40-49 2 6 (I.36 
50-59 3 2 0.~(1 
60-69 3 I 0.44 
Mean 46 + 15 41 + 11 0.39 
Calcium antagonist (diltiazem) (rag/day) 212 -_ 31 203 +_ 35 0.44 
Sustained-release ISDN (mg/day) 57 = 8 58 _+ 7 0.83 
Data presented are mean value - SD or number of patients, unless 
otherwise indicated. Abbreviations as in Table 1. 
persisted throughout the follow-up period. Over the follow-up 
period, 22 of the 29 patients had a second or a third hot phase. 
During the repeated hot phases, all 22 patients required 
readmission and showed frequent ischemic episodes of ST 
segment changes recorded on ambulatory ECG monitoring or 
rest 12-lead ECG monitoring in hospital. Of the remaining 
seven patients who did not experience a repeated hot phase 
but had regular vasospastic anginal attacks, three showed ST 
segment elevation during an exercise test early in the morning, 
and four had ST segment elevation on Holter monitoring out 
of hospital during follow-up. 
Angiographic procedure. The present study was approved 
by the hospital ethics committee, and written informed consent 
was obtained from each patient. All patients were admitted to 
the coronary care unit before the study. Sublingual nitroglyc- 
erin was administered asrequired, but calcium antagonists and 
oral nitrates were gradually tapered, and calcium antagonists 
were discontinued for 36 h and oral nitrates for 24 h before the 
study. Coronary angiography was performed in the morning 
(from 8:30 AM to 11 AM) by the Sones technique at Anjo Kosei 
Hospital in Japan. After baseline angiograms uitable for 
quantitative analysis of the right and left coronary arteries had 
been obtained, 0.2 mg of ergonovine maleate was administered 
intravenously by a rapid bolus injection. Radiographic projec- 
tions were identical during the sequential ngiographic studies. 
Heart rate and aortic pressure were monitored continuously, 
and 12-lead ECGs were recorded at 30-s intervals. Whenever 
chest pain or significant ST segment changes were observed, 
selective coronary angiograms were immediately obtained. 
Coronary vasospasm was relieved by isosorbide dinitrate, given 
as one or two intracoronary boluses to a total of 5 rag. To 
exclude the possibility of persistent spasm, we gave a dose 
(5 mg) of intracoronary isosorbide dinitrate that was greater 
than the dose previously demonstrated (30,31) to achieve 
maximal coronary vasodilation in patients with vasospastic 
angina (3 rag). The follow-up angiogram was obtained in the 
same angiographic projection as the initial angiogram after 
viewing the initial angiographic records and cine film. Then, 
the response to ergonovine and the severity of fixed stenoses 
were quantified in the matched views of the initial and 
follow-up angiograms using the quantitative angiographic anal- 
ysis system. No complications occurred uring the repeated 
ergonovine provocation tests and the angiographic procedures. 
Quantitative coronary angiographic analysis. The new 
version of the computer-based coronary angiography analysis 
system (CAAS II) (32,33) was used to perform the quantitative 
analysis in a core angiographic laboratory (Cardialysis, Rotter- 
dam, The Netherlands). The CAAS analysis has been de- 
scribed in detail elsewhere (33-39). Briefly, the entire cine 
frame of 18 x 24 mm is digitized at a resolution of 1,329 × 
1,772 pixels. Correction for pin-cushion distortion is per- 
formed before analysis. Boundaries of a selected coronary 
segment are detected automatically. The absolute diameter of 
the stenosis in millimeters is determined using the guiding 
catheter as a scaling device (40). To standardize the method of 
analysis of the initial and follow-up angiograms, all study 
frames selected for analysis were end-diastolic to minimize 
motion artifact, and arterial segments were measured between 
the same identifiable branch points at baseline, after adminis- 
tration of ergonovine and after administration f isosorbide 
dinitrate (41,42). 
In the CAAS II system (32-42), minimal umen diameter 
was determined by computer-based ge-detection contour 
using minimal cost criteria. The CAAS II system determines 
the size at the target coronary segment using a computer- 
derived interpolated reference diameter rather than an operator- 
selected reference point. The interpolated reference diameter 
is derived from the edge-detection diameter function of the 
nonstenotic/nonspastic proximal and distal subsegments. The 
reference vessel diameter values are estimated by fitting a 
straight line to the diameter function proximal and distal to the 
obstruction followed by a shift such that 80% of the diameter 
values are below the adjusted straight line. This line then 
represents the reconstructed reference diameter function and 
gives an estimate of the arterial size at each point along the 
analyzed coronary segment. The interpolated reference vessel 
diameter is taken as the value of the reconstructed diameter 
function at the position of the minimal umen diameter. The 
advantages of this approach are that it is essentially user 
independent, and thus highly reproducible, and that every 
measurement is based on multiple measurements (every scan 
line) proximal and distal to the lesion. 
Segments analyzed. The coronary segments were coded 
according to the recommendations of the American Heart 
Association (AHA) (43). One AHA segment from each of the 
three major epicardial vessels was analyzed. For vessels that 
demonstrated vasospasticity, he segment in which vasospasm 
occurred was analyzed. For vessels in which no vasospasm 
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Figure 1. Reference (dotted line) and minimal lumen 
diameter (solid line) changes atbaseline and after admin- 
istration of ergonovine and isosorbide dinitrate (ISDN) at 
both initial and follow-.,p angiography in group 1. A, After 
administration f ergonovine, minimal lumen diameter 
constricted significantly in 16 spastic segments of 16 
vessels at both the initial and follow-up tests. B, Reference 
and minimal lumen diameter responses to ergonovine 
were equivalent i  23 nonspastic segments of23 vessels at 
both the initial and follow-up tests. 
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occurred, the AHA segment analyzed was that which had the 
most diseased appearance. Quantitative angiographic analysis 
provided the minimal lumen and reference vessel diameters 
for all AHA segments analyzed. 
Statistical analysis. The unpaired Student  test was used 
to compare the two groups of patients. Differences between 
proportions were analyzed by the cfii-square test with correc- 
tion; p < 0.05 was considered significant. 
Resu l ts  
Clinical characteristics. All patients demonstrated persis- 
tent symptoms of vasospastic angina with ischemic ST segment 
changes during follow-up that were detected by in-hospital 
12-lead or ambulatory ECG monitoring, or both, or Holter 
monitoring out of hospital. Medication was a combination of a 
calcium antagonist (diltiazem) and sustained-release i osor- 
bide dinitrate. Although the medication reduced the frequency 
of ischemic attacks, symptoms of variant angina persisted 
throughout the follow-up period. 
The ECG and angiographic results for all 29 patients are 
presented in Table 1. The location of myocardial ischemia 
indicated by ECG changes and the spastic coronary segment 
shown by angiography were similar at the initial and follow-up 
tests in 13 patients (group 1, Patients 1 to 13) but were 
different at follow-up in 16 (group 2, Patients 14 to 29). With 
regard to clinical characteristics, no significant differences were 
found between groups 1 and 2 for age (56 _+ 7 vs. 54 _+ 9 years); 
gender (1 of 13 vs. 2 of 16 female patients); coronary risk 
factors, such as hypertension, diabetes, moking and hypercho- 
lesterolemia; nd average serum cholesterol level (Table 2). 
The mean interval to angiographic follow-up (46 + 15 vs. 41 _+ 
11 months) was similar in the two groups, and there was no 
significant difference in medication. 
Location of coronary spasm. In group 1, no fluctuation i  
location of vasospasticity was observed at follow-up. In group 
2, fluctuation of spastic location was observed at follow-up in 
22 (46%) of 48 vessels. 
Group 1. The average minimal umen and reference diam- 
eters of 16 spastic segments in 13 patients at baseline, after 
administration of ergonovine and after administration of 
isosorbide dinitrate at the initial and follow-up tests are shown 
in Figure 1A. Coronary spasm was observed in 16 segments of 
16 vessels in group 1: Minimal lumen diameter decreased after 
administration of ergonovine from 1.75 _+ 0.43 to 0.55 _+ 
0.40 mm during initial angiographic study and decreased from 
1,57 + 0.44 to 0.52 + 0.39 mm at follow-up. The minimal 
lumen and reference diameters of the remaining 23 nonspastic 
segments of 23 nonspastic vessels in group 1 are shown in 
Figure lB. The response to ergonovine (minimal umen diam- 
eter reduction) between the two tests was similar in these 23 
nonspastic segments. 
Group 2. Coronary spasm was observed in 23 segments at 
initial angiography (Fig. 2A). At follow-up, 13 of the 23 
segments howed persistent vasospastic activity, but the re- 
maining 10 segments howed no vasospasm. The minimal 
lumen and reference diameter changes for the remaining 25 
segments of 25 vessels in group 2 are shown in Figure 2B. No 
spasm was observed at the initial test in these 25 segments, but 
at follow-up, 12 of the 25 exhibited vasospasm after ergonovine, 
and 13 had no vasospasm. An example of angiographic evidence 
of fluctuation i  vasospastic location between i itial and follow-up 
angiography in a patient in group 2 is shown in Figure 3. 
Discuss ion  
Quantitative coronary angiography and repeated ergono- 
vine provocation tests demonstrated that in some patients with 
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Figure 2. Reference (dotted line) and minimal lumen 
diameter (selid line) changes at baseline and after 
administration f ergonovine and isosorbide dinitrate 
(1SDN) at initial and follow-up angiography in group 
2. A, In 13 of the 23 initially spastic segments, minimal 
lumen diameter educed from 1.65 -+ 0.44 to 0.39 -+ 
0.44 mm and vasospasm was again demonstrated at
follow-up, whereas in the remaining 10 segments, 
vasospasm was not observed at follow-up. B, In 12 of 
the 25 initially nonspastic segments, minimal umen 
diameter decreased from 1.76 _+ 0.23 to 0.51 _+ 
0.34 mm and vasospasm was demonstrated atfollow- 
up, whereas in the remaining 13 segments, vasospasm 
was not observed at follow-up. 
persistent variant angina, spasm may fluctuate from one vessel 
to another over a period of several years, whereas in others the 
location of coronary spasm is fixed over time. 
Previous studies. Although several studies have reported 
the spontaneous remission of vasospastic angina (14-17), 
persistence of symptoms of variant angina has been reported in 
other studies with long-term follow-up of up to 10 years 
(17-20). Although Kaski et al. (21) recently reported the 
consistency of angiographic location of vasospasm in 10 pa- 
tients with variant angina despite medical therapy, conflicting 
and indirect evidence from previous ECG studies (14,22,23) 
suggests that the location and degree of coronary spasm may 
not be fixed. In a nonquantitative coronary angiographic study 
(18), we previously showed that percent diameter stenosis as 
assessed visually may fluctuate over time, although the relation 
of such relative measures to atherosclerosis was not explored. 
Waters et al. (14) reported that the location of myocardial 
ischemia indicated by ST segment changes at follow-up was 
similar to that at the initial ergonovine test. However, the 
direction of ST segment shifts (elevation or depression) 
changed in 3 of 10 patients who had repeated vasospastic 
attacks at follow-up. Previtali et al. (23) reported that differ- 
ence of location of myocardial ischemia s determined by ST 
segment changes was observed in a single patient, yet the dose 
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Figure 3. Initial and follow-up coronary, angiograms and quantitative angiographic analysis from Patient 17, group 2. Angiograms AI, A2, C1 and 
C2 of the left anterior descending coronary artery were obtained in the right anterior oblique projection; angiograms B1, B2, D1 and D2 of the 
right coronary artery were obtained in the left anterior oblique projection. Initial angiograms were obtained at baseline (AI and B1) and after 
administration of0.2 mg of intravenous ergonovine (A2 and g2). After administration f ergonovine, minimal luminal diameter decreased from 1.89 to 
0.73 mm, and a transient 67% lumen narrowing (coronary spasm) was observed in American Heart Association (AHA) segment 7 of the left anterior 
descending coronary artery {A2), and minimal lumen diameter decreased from 2.35 to 1.56 ram, with no coronary spasm observed, inAHA segment 3 
of the right coronary artery (B2). Follow-up angiograms CI and D1 were obtained before (control) and angiograms C2 and D2 after 0.2 nag of intravenous 
ergonovine. After administration f ergonovine, minimal luminal diameter decreased from 2.09 to 1.54 mm, and no vasospasm was observed in AHA 
segment 7 of the left anterior descending coronary artery (C2), the site of previously observed spasm. However, in AlIA segment 3 of the right coronary 
artery (D2), minimal lumen diameter decreased from 2.11 to 0.61 ram, and a new, transient 75% lumen narrowing (vasospasm) was observed. (Figure 
3 continued on page 1612.) 
of ergonovine required to induce vasospasm was different at 
follow-up in the majority of patients. Whittle et al. (22) 
reported that variable and unpredictable ECG responses to 
repeated ergonovine tests were observed in 6 of 10 patients, 
whereas the remaining 4 exhibited reproducible ECG re- 
sponses to ergonovine. Our quantitative coronary angiographic 
study clearly demonstrated that the location of coronary spasm 
was variable in some patients with persistent symptoms of 
angina. The variability of ECG changes een during recurrent 
vasospastic angina attacks may be due to these phenomena. 
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Figure 3. Contbmed 
Proposed mechanism of spatial fluctuation of coronary 
spasm. The mechanism of fluctuation of vasospasm is still 
unknown. It has been proposed that the parasympathetic 
nervous ystem may play a role in the pathogenesis ofvariant 
angina (44), and variation in autonomic tone may therefore 
contribute to fluctuations in vasospastic behavior. Recent 
experimental studies (45-50) demonstrate that several 
endothelium-derived factors mediate vascular smooth muscle 
tone and that damaged endothelium ay play a major role in 
the pathogenesis ofvasospasm. Endothelial damage may occur 
even in the early stages of atherosclerosis (48-50). Zeiher et al. 
(51) indicated that abnormal vasoconstriction was observed in 
early atherosclerotic s tes in patients without variant angina, using 
intracorona~ ultrasound. Yamagishi et al. (52) reported that 
early stages of atherosclerosis were observed by intracoronary 
ultra~und at the site of spasm in patients with variant angina. 
In our study, although the minimal umen diameter of fixed 
stenosis tended to be smaller at follow-up than at the initial 
angiogram in 9 of 12 new spastic segments, in 8 of 10 previous 
spastic segments the minimal umen diameter of fixed stenosis 
tended to be larger at follow-up. Both Waters et al. (53) and 
our group (54) recently reported that the standard eviation of 
repeated quantitative measurements with the CAAS system of 
serial clinical coronary angiograms i _+0,20 ram, and a differ- 
ence greater than twice the standard eviation for repeated 
measurements of the CAAS system may represent a true 
change with >95% confidence. If we adopt a per-lesion 
categoric approach to the definition of progression or regres- 
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sion of atherosclerosis, we would include only lesions with a 
change >0.40 mm at follow-up. If such a categoric approach 
were applied, then a significant progression occurred in 
group 2 with 95% confidence in 2 of 12 new spastic 
segments, and significant regression was not seen in any new 
spastic segments (0 of 12). Significant progression of fixed 
atherosclerosis was not observed in any previously spastic 
segments in which spastic activity was no longer provoked (0 
of 10), and significant regression was seen in 2 of 10 previous 
spastic segments. If a continuous statistical approach is 
adopted in which the mean change in minimal lumen 
diameter is analyzed for the study group, we find that in 
Group 2 the minimal lumen diameter after administration 
of isosorbide dinitrate at new spastic segments was signifi- 
cantly smaller at follow-up than that at initial angiography 
(2.44 m 0.32 mm initially vs. 2.29 +_ 0.30 mm at follow-up, 
p < 0.05). However, the minimal lumen diameter in previ- 
ous spastic segments, which demonstrated vasospasm at 
initial angiography but not at follow-up, was significantly 
larger at follow-up than at initial angiography (2.24 _+ 
0.51 mm initially vs. 2.40 _+ 0.42 mm at follow-up, p < 0.05). 
Thus, if a continuous statistical approach is adopted for 
each study cohort, we observe that the development of 
spasm at a new site is associated with a reduction, and the 
disappearance of spasm with an improvement, in minimal 
lumen diameter after isosorbide dinitrate. 
The present data lend support to the concept hat fluctua- 
tion of spastic locations might relate to the pathologic process 
of local progression and regression of early atherosclerosis in 
coronary arteries. Clearly, a large prospective (and probably 
multicenter) trial with long-term angiographic follow-up and 
repeated ergonovine testing would be required to definitively 
establish this point. 
Conclusions. Quantitative coronary angiography and re- 
peated ergonovine provocation tests demonstrate that in some 
patients with persistent variant angina, spasm may fluctuate 
from one vessel to another over a period of several years, 
whereas in others the location of coronary spasm is fixed over 
time. Vasospastic angina may not only be a transient disease 
restricted in location, but may also be a persistent and variable 
condition involving multiple vessels over many years. 
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